KLP Kapitalforvaltning AS acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) in the ...

Thrivent Financial for Lutherans reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 83.2% in ...

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents. Halozyme said ...

Canada is currently the US’ largest uranium producer, delivering 27 percent of its total supply, followed by Australia and ...

Halozyme Therapeutics, Inc. (HALO) shares up after passing $1 billion in revenue for first time, strong guidance.

The gold market continues to see a lot of buyers jumping into it every time we fall. This has been the same situation we find ourselves in on Thursday, as the market had a rough Asian session.

Highlights,PNC Financial Services Group Inc. adjusted its stake in Halozyme Therapeutics, reflecting a shift in market ...

Halozyme Therapeutics, Inc. is headquartered in San Diego, CA. The company has a somewhat unique business model as it uses its proprietary ENHANZE drug delivery platform to improve or "enhance ...

Halozyme stock is in a consolidation pattern but its chart shows an alternate entry. The biotech name hit two milestones in 2024.